VCYT — Veracyte, Inc. stock price, charts and financials

QT71Veracyte, Inc.

Veracyte, Inc. (NASDAQ: VCYT) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
46.41
+1.56+3.48%
OverviewShort InterestFilings
VCYTQT71Veracyte, Inc.·NASDAQ
46.41+3.48%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
SHC+0.67%$18.11NEOG-0.76%$11.81RDNT+3.62%$69.22CDNA-1.59%$47.09TWST-1.59%$99.45BLLN+3.59%$142.25QGEN+0.00%$42.33PSNL+2.42%$13.52
Snapshot
Index-P/E33.15EPS (ttm)1.40Insider Own2.78%Shs Outstand79.79MPerf Week-16.60%
Market Cap3.70BForward P/E25.09EPS next Y1.85Insider Trans-13.36%Shs Float79.46MPerf Month-19.98%
Enterprise Value3.26BPEG4.47EPS next Q0.44Inst Own-Short Float8.40%Perf Quarter38.74%
Income114.00MP/S6.59EPS this Y28.42%Inst Trans-Short Ratio5.61Perf Half Y21.62%
Sales562.00MP/B2.67EPS next Y2.88%ROA7.70%Short Interest6.67MPerf YTD10.24%
Book/sh17.40P/C7.64EPS next 5Y7.41%ROE8.64%52W High60.91 -23.81%Perf Year96.32%
Cash/sh6.08P/FCF22.34EPS past 3/5Y-ROIC6.59%52W Low23.35 98.76%Perf 3Y65.16%
Dividend Est.-EV/EBITDA24.68Sales past 3/5Y20.29% 34.60%Gross Margin72.20%Volatility7.63% 5.29%Perf 5Y24.76%
Dividend TTM-EV/Sales5.80EPS Y/Y TTM351.61%Oper. Margin16.98%ATR (14)3.67Perf 10Y843.29%
Dividend Ex-Date-Quick Ratio9.16Sales Y/Y TTM26.01%Profit Margin20.37%RSI (14)35.97Recom2.38
Dividend Gr. 3/5Y-Current Ratio9.16EPS Q/Q22.73%SMA20-16.97%Beta1.91Target Price55.57
Payout0.00%Debt/Eq0.03Sales Q/Q15.38%SMA50-12.98%Rel Volume1.45Prev Close44.85
Employees755LT Debt/Eq0.03EarningsNov 03SMA20010.49%Avg Volume1.37MPrice46.41
IPO DateOct 29, 2013Option/ShortYes / YesEPS/Sales Surpr.26.19% 3.96%Net Debt/EBITDA-1.95Volume1,985,988Change3.48%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedMorgan StanleyUnderweight$47 → $44
Aug-04-26ReiteratedStephensOverweight$68 → $55
Aug-04-26ReiteratedPiper SandlerOverweight$66 → $54
Aug-03-26ReiteratedCanaccord GenuityHold$60 → $50
Jul-31-26ReiteratedNeedhamBuy$57 → $69
Jul-30-26ReiteratedNeedhamBuy$57 → $69
Jul-15-26ReiteratedPiper SandlerOverweight$66
Jul-14-26ReiteratedCanaccord GenuityHold$42 → $60
Jul-09-26ReiteratedMorgan StanleyUnderweight$37 → $47
Jun-29-26ReiteratedGuggenheimBuy$50 → $65
Latest News
Jul-31-26
Jul-31-2608:34AM
Veracyte, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
12:23AM
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcriptseekingalpha.com
Jul-30-26
Jul-30-2607:06PM
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimateszacks.com
04:05PM
Veracyte Announces Second Quarter 2026 Financial Resultsglobenewswire.com
Jul-28-26
Jul-28-2604:05PM
Veracyte to Participate in Upcoming Investor Conferencesglobenewswire.com
Jul-26-26
Jul-26-2603:53AM
First Trust Advisors LP Buys 833,543 Shares of Veracyte, Inc. $VCYTdefenseworld.net
Jul-24-26
Jul-24-2612:30PM
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near ResistanceChartMill
Jul-23-26
Jul-23-2611:06AM
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Declinezacks.com
08:15AM
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?fool.com
04:07AM
Fifth Third Bancorp Purchases 52,043 Shares of Veracyte, Inc. $VCYTdefenseworld.net
Jul-21-26
Jul-21-2608:40AM
Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout SetupChartMill
07:57AM
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?fool.com
03:16AM
Amova Asset Management Americas Inc. Has $33.63 Million Holdings in Veracyte, Inc. $VCYTdefenseworld.net
Jul-15-26
Jul-15-2601:56PM
Artisan Mid Cap Fund Q2 2026 Performance Reviewseekingalpha.com
06:59AM
This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga.com
Company

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue56251744636129722011712092
Cost of Goods Sold Incl. D&A15615714811310274413733
Gross Profit406360298248195145768459
Selling, General and Administrative Excl. Other202211206184174181898365
Research and Development937169574130171515
Other Operating Expense1447932116511
Operating Income967416-86-41-82-35-15-22
Interest Expense000000012
Unusual Expense
—————————
Non-Operating Income (Expense)21-610950131
Net Income Before Taxes1176826-77-36-82-35-13-23
Income Taxes122-20-6000
Consolidated Net Income1146624-74-37-76-35-13-23
Net Income From Continuing Operations1146624-74-37-76-35-13-23
Net Income1146624-74-37-76-35-13-23
EPS (Recurring)1.440.840.32-1.02-0.51-1.11-0.66-0.27-0.62
EPS (Basic, Before Extraordinaries)1.440.840.32-1.02-0.51-1.11-0.66-0.27-0.62
EPS (Diluted)1.400.820.31-1.02-0.51-1.11-0.66-0.27-0.62
EBITDA1329049-49-7-60-27-8-17
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio33.1551.34127.74——————
Price To Sales Ratio6.616.436.755.565.7512.7322.1710.705.06
Gross Margin72.2469.6366.8268.7065.6665.9164.9670.0064.13
Operating Margin17.0814.313.59-23.82-13.80-37.27-29.91-12.50-23.91
Net Margin20.2812.775.38-20.50-12.46-34.55-29.91-10.83-25.00
Shares Outstanding807976737268534637
Market Capitalization3,7133,3263,0102,0081,7092,8022,5941,284465
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$66.11$53.93$41.76$29.59$17.41● Close Price0.00M2.04M4.08M6.11M8.15MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
EASTHAM KARINDirectorJun 18 '26Sale52.893,729197,23415,097Jun 22
Leite JohnGlobal Chief Commercial OffJun 04 '26Sale50.0713,975699,732132,305Jun 04
McGuire AnnieEVP, General CounselJun 04 '26Sale49.763,176158,036137,240Jun 04
Chambers RebeccaChief Financial OfficerJun 04 '26Sale49.733,561177,083173,280Jun 04
Stapley MarcChief Executive OfficerJun 04 '26Option Exercise36.60138,0515,052,667578,545Jun 04
Stapley MarcChief Executive OfficerJun 04 '26Sale50.12138,0516,919,585440,494Jun 04
Wygant JonathanVP, Chief Accounting OfficerMay 22 '26Option Exercise24.8024,000595,20069,434May 27
Wygant JonathanVP, Chief Accounting OfficerMay 22 '26Sale45.4024,0001,089,62445,434May 27
EPSTEIN ROBERT SDirectorMay 20 '26Sale44.0110,000440,12952,446May 22
McGuire AnnieSVP, General CounselMay 06 '26Sale39.0210,204398,211143,708May 08
Chambers RebeccaChief Financial OfficerMar 04 '26Sale36.1418,341662,869131,196Mar 06
Stapley MarcChief Executive OfficerMar 04 '26Sale35.9745,5231,637,594357,554Mar 06
Leite JohnChief Commercial Officer-CLIAMar 04 '26Sale35.195,260185,083107,580Mar 06
McGuire AnnieSVP, General CounselMar 04 '26Sale35.556,658236,72594,706Mar 06
Febbo Phillip G.Chief Scientific & Med OfficerMar 02 '26Sale36.1613,425485,429117,346Mar 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.